Short answer
MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). July 27, 2026 conference call covering topline ZEPHYR Phase 2 results.
MapLight Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- July 27, 2026 conference call covering topline ZEPHYR Phase 2 results
- ML-007C-MA evaluated in inpatient adults with schizophrenia and acute psychosis exacerbation
- Presentation furnished as Exhibit 99.1, providing the key disclosed trial data
- Results may materially influence MapLight’s clinical-development outlook and investor expectations
Item 8.01 · Other Events
- July 27, 2026 press release announced results from MapLight’s ZEPHYR clinical trial
- Trial results may affect investors’ assessment of development progress and regulatory prospects
- Full findings and material data appear in Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.2
- Phase 2 ZEPHYR met its primary endpoint: 210/3 mg BID reduced PANSS by 4.5 points versus placebo, effect size 0.37, p=0.015
- Prespecified cognitive improvement supports differentiation: effect size 0.51, 0.44-point benefit, p=0.041, independent of psychosis reduction
- Favorable tolerability profile: 19.9% active-arm discontinuation, 2% GI-related discontinuation, no drug-related severe adverse events or urinary-retention signal
- Results support advancing 210/3 mg BID into an additional confirmatory pivotal trial, subject to FDA end-of-Phase 2 feedback
- VISTA Alzheimer’s disease psychosis trial continues with topline results expected in 2H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MapLight Therapeutics, Inc. 8-K filings
Get the next MPLT 8-K as it lands
Follow MPLT for push alerts, or ask the research agent what this filing means.